Abstract
Therapeutic Drug Monitoring (TDM), to measure drug and anti-drug antibodies and guide therapeutic adjustments, has been associated with positive clinical outcomes when using biologics such as infliximab (IFX) to treat inflammatory bowel disease (IBD). TDM may be ordered reactively or proactively as the preferred standard of care versus empiric dosing. This study aims to estimate the 2021 incremental budgetary change in per member per year (PMPY) in the US when a proactive TDM approach is implemented for IBD patients treated with IFX.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
